Transparency Statement

TIF’s funding derives from a number of sources including international and regional funds, industry, generous donors, organisations in the pursuit of their common interest in haemoglobin disorders (thalassaemia and sickle cell disease).

The overall proportion of industry related funding (sub-total in %) is 17.09% and the non-industry funding is 82.85%. The highest contribution from a single company is 8.47 %.